Ignite Creation Date:
2025-12-24 @ 7:51 PM
Ignite Modification Date:
2026-07-06 @ 1:50 AM
Study NCT ID:
NCT05907304
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-22
First Post:
2023-05-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Sponsor:
Erasca, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced or Metastatic Solid Tumors | View |